In this single-blind crossover study the antihypertensive efficacies of two dihydropyridine
calcium antagonists, sustained-release isradipine and lacidipine, were compared using …

The antihypertensive effect of isradipine was assessed by repeated 24-h ambulatory blood
pressure monitoring. Using an SPS device (Sandoz Pharma, Basel, Switzerland), monitoring …

The antihypertensive efficacy of sustained-release isradipine administered once daily
compared to the immediate-release formulation administered twice daily was assessed by …

Isradipine, a new antihypertensive dihydropyridine calcium antagonist, was evaluated for its
efficacy, tolerability, and safety in 91 ambulatory patients who had mild-to-moderate …

The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years,
with hypertension. After withdrawal of previous antihypertensive treatment and a four-week …

To evaluate the magnitude and duration of the antihypertensive effect of sustained release
(SRO) isradipine, 37 uncomplicated essential hypertensive patients (diastolic blood …

Isradipine, a new calcium channel blocker, was given to 32 patients with mild to moderate
essential hypertension. After a run-in period of three weeks, 32 patients were randomized …

In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler
echocardiographic data to investigate the antihypertensive and hemodynamic effects of …

Twenty-four-hour ambulatory blood pressure (BP) monitoring allows the physician to follow
the course of blood pressure of a patient at the worksite, at home, and during sleep. All these …

Twenty-three middle-aged men (59+/-2 years) with sustained, essential hypertension (WHO
Stage II) and with diastolic blood pressure exceeding 100mmHg during a run-in placebo …